BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22481485)

  • 1. The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat.
    Tai LM; Jacobsen H; Ozmen L; Flohr A; Jakob-Roetne R; Caruso A; Grimm HP
    J Pharmacokinet Pharmacodyn; 2012 Jun; 39(3):227-37. PubMed ID: 22481485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses.
    Lu Y; Riddell D; Hajos-Korcsok E; Bales K; Wood KM; Nolan CE; Robshaw AE; Zhang L; Leung L; Becker SL; Tseng E; Barricklow J; Miller EH; Osgood S; O'Neill BT; Brodney MA; Johnson DS; Pettersson M
    J Pharmacol Exp Ther; 2012 Aug; 342(2):366-75. PubMed ID: 22562771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
    Best JD; Jay MT; Otu F; Churcher I; Reilly M; Morentin-Gutierrez P; Pattison C; Harrison T; Shearman MS; Atack JR
    J Pharmacol Exp Ther; 2006 May; 317(2):786-90. PubMed ID: 16443723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
    Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
    J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
    Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
    J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
    Hook G; Hook V; Kindy M
    J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.
    Portelius E; Zetterberg H; Dean RA; Marcil A; Bourgeois P; Nutu M; Andreasson U; Siemers E; Mawuenyega KG; Sigurdson WC; May PC; Paul SM; Holtzman DM; Blennow K; Bateman RJ
    J Alzheimers Dis; 2012; 31(2):335-41. PubMed ID: 22531418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.
    Cook JJ; Wildsmith KR; Gilberto DB; Holahan MA; Kinney GG; Mathers PD; Michener MS; Price EA; Shearman MS; Simon AJ; Wang JX; Wu G; Yarasheski KE; Bateman RJ
    J Neurosci; 2010 May; 30(19):6743-50. PubMed ID: 20463236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease.
    Portelius E; Zhang B; Gustavsson MK; Brinkmalm G; Westman-Brinkmalm A; Zetterberg H; Lee VM; Trojanowski JQ; Blennow K
    Neurodegener Dis; 2009; 6(5-6):258-62. PubMed ID: 19955704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
    Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
    J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid β-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses.
    Lu Y; Barton HA; Leung L; Zhang L; Hajos-Korcsok E; Nolan CE; Liu J; Becker SL; Wood KM; Robshaw AE; Taylor CK; O'Neill BT; Brodney MA; Riddell D
    Neurodegener Dis; 2013; 12(1):36-50. PubMed ID: 22922480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells.
    Jämsä A; Belda O; Edlund M; Lindström E
    J Biomed Sci; 2011 Oct; 18(1):76. PubMed ID: 22018341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling effect of a γ-secretase inhibitor on amyloid-β dynamics reveals significant role of an amyloid clearance mechanism.
    Das R; Nachbar RB; Edelstein-Keshet L; Saltzman JS; Wiener MC; Bagchi A; Bailey J; Coombs D; Simon AJ; Hargreaves RJ; Cook JJ
    Bull Math Biol; 2011 Jan; 73(1):230-47. PubMed ID: 20411345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression.
    Burton CR; Meredith JE; Barten DM; Goldstein ME; Krause CM; Kieras CJ; Sisk L; Iben LG; Polson C; Thompson MW; Lin XA; Corsa J; Fiedler T; Pierdomenico M; Cao Y; Roach AH; Cantone JL; Ford MJ; Drexler DM; Olson RE; Yang MG; Bergstrom CP; McElhone KE; Bronson JJ; Macor JE; Blat Y; Grafstrom RH; Stern AM; Seiffert DA; Zaczek R; Albright CF; Toyn JH
    J Biol Chem; 2008 Aug; 283(34):22992-3003. PubMed ID: 18574238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.